Summary
The cathelicidin, antimicrobial peptide found in mammals, LL-37 is
the only known human cathelicidin to confer protection from
bacterial infection. Despite the high bacterial toxicity, the clinical
application was very limited due to high number of serious side
effects. Researchers at the University of Nebraska Medical Center
successfully have modified LL-37 to produce novel compound with
highly selective antimicrobial activity and reduced side toxicity.

Market Value
With antibiotic resistance on the rise, the need for new anti-bacterial
is constant and crucial around the globe. New anti-bacterial, such
as the modified LL-37, will be able to provide valuable alternatives
through out the world.

Features and Benefits
oHigh selectivity
oLow side toxicity
oDerivative of naturally occurring peptide
oProven antimicrobial activity of natural peptide

Issued (TID - 09)

UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with the University of Nebraska Medical Center.